13h00-14h00: Welcome

14h00-15h00: Session 1: Clinical aspects: epidemiology, physiopathology, immunology

• Juliette Riger – CHU, Besançon. Optimising screening for Pseudomonas aeruginosa gastrointestinal colonisation in intensive care patients
• Adrien Biguenet – CHU, Besançon. 15 years of evolution and interspecies spread of blaIMP-29 following a hospital outbreak of Pseudomonas aeruginosa
• Olympe Bonnardel – UMR 6249, Chrono-environnement, Besançon. Is phage resistance the key of bacterial epidemic clones?
• Nadia Jaidane – CNR de la résistance aux antibiotiques, Le Kremlin-Bicêtre. Genomic insights in carbapenemases producing Pseudomonas spp from Tunisia

15h00-15h45: Plenary Session – invited speaker

• Steve Lory – Department of Microbiology, Harvard Medical School, Boston. Probing the Pseudomonas aeruginosa periplasm with inhibitory nanobodies

15h45-17h15: Poster Session

17h15-17h30: Sponsors

17h30-19h: Session 2: New antibiotics and non-antibiotic therapies

• Shahriar Safari – Institut Pasteur, Lille. Siderophore–Metallo-β-Lactamase Inhibitor Conjugates Reverse NDM-Mediated Resistance to Meropenem and Cefiderocol in Pseudomonas aeruginosa
• Isabelle Broutin – CiTCoM, Université Paris Cité. Rational Approach Guided by Structural Biology for the Design of Peptidomimetics Inhibiting Efflux Pumps in Pseudomonas aeruginosa
• Rebecca Martedi – University of Urbino, Italy. Targeting de novo L-cysteine biosynthesis (DeNoCB) in Pseudomonas aeruginosa for novel antimicrobial strategies
• Victor Tardivy-Casemajor – IBS, Grenoble. Development of human monoclonal antibodies for therapeutic use against virulence factors of Pseudomonas aeruginosa
• Julien Buyck – U1070 PHAR2, Poitiers. Animal-Free PK/PD Index Prediction for Meropenem against Pseudomonas aeruginosa using In Vitro Time-Kill Data and Mixed-Effects Modeling
• Rozenn Le Berre – UMR 1070, Brest. Intranasal Levilactobacillus brevis and Ligilactobacillus salivarius reduce bacterial burden and reshape lung immune responses in murine Pseudomonas aeruginosa pneumonia

19h: Networking

8h30-9h45: Session 3: Host-pathogen interactions and virulence factors

• Marion Lafon – P3Cell, Reims. NAD(P)H quinone oxidoreductases enable Pseudomonas aeruginosa to resist the airway epithelium’s antibacterial oxidative response
• Vincent Deruelle – Institut Pasteur, Paris. Understanding how ExoY-mediated cGMP signaling contributes to Pseudomonas aeruginosa virulence
• Nicolas Gomez – Helmholtz Center for Infection Research, Braunschweig, Germany. MiaA-mediated tRNA modifications couple tryptophan attenuation and changes in tRNA abundance to complex phenotypes in aeruginosa
• Romé Voulhoux – LCB, Marseille. Structure-function exploration of dynamic processes in bacterial type II secretion
• Sylvain Brax – Centre de recherche de Saint-Antoine, Paris. Degradation of the septin cytoskeleton in the bronchial epithelium by aeruginosa

9h45-11h: Coffee break + Poster Session

11h-12h15: Session 4: Environmental adaptation and bacterial interactions

• Yann Héchard – Laboratoire Ecologie Biologie des Interations, Poitiers. An environmental amoeba associated with Pseudomonas aeruginosa and co!
• Aurélia Rousset – CIRI, Lyon. Study of the in vivo evolution of aeruginosa and its interactions with S. aureus
• Darina Colcanap – LIBio, Nancy. A study of antagonistic interaction networks to understand the diversity and ecology of Pseudomonas species that spoil dairy products
• Sibylle Lebert – MIO, Université de Toulon. Bacterial Ice Nucleation as a survival strategy in glacial environments
• Florine Girard-Blanc – EBI, Poitiers. A conserved RbdA/1-undecene system shapes volatile communication in Pseudomonas

12h15-14h00: Break + Poster Session

14h00-15h45: Session 5: Chronic infection, biofilm and antibiotic resistance

• Audrey Le Gouëllec, TIMC, Grenoble. Untargeted LC-HRMS/MS metabolomics identifies polyamine-driven metabotypes in longitudinal clinical isolates of Pseudomonas aeruginosa
• Floriane Costes – LPHI, Montpellier. A new in vivo model to assess bacterial persistence and host inflammation upon mono- or co-infection with aeruginosa isolates from CF patients
• Lucas Pereira – CNR Résistance aux antibiotiques, Besançon. The CpxRS two-component system as a new regulator of β-lactam resistance in clinical strains of Pseudomonas aeruginosa
• Coralie Fumeaux – Institute of Microbiology, Lausanne, Switzerland. A novel operon involved in septal cell wall synthesis and beta-lactam resistance in Pseudomonas aeruginosa
• Julien Hérenval – IGDR, Rennes. Modelling of antibiotic gradients and biofilm dynamics: The MicroDyn project
• Anne-Eloïse Revillot–Schmidt – IBSC, Illkirch. The importance of the citrate mediated iron import pathway in Pseudomonas aeruginosa

15h45-16h15: Discussion/conclusion